Time trends of consumption and costs of drugs in a cancer referral centre

Antonio Marfella, Francesco Perrone, Simona Creazzola, M. Rosaria Salzano, Silvio Monfardini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study is a descriptive analysis of the consumption and the costs of antineoplastic chemotherapeutic agents and of the major groups of drugs used for supportive therapy during the 1990-1995 period, at the National Cancer Institute of Naples, Italy. Increasing consumption trends were observed for methotrexate, vinorelbine, oxazophorines (cyclophosphamide + ifosfamide), epirubicin, dacarbazine and 5-fluorouracil; stable trends for etoposide, mitomycin C, bleomycin, vincristine + vindesine, and platinum compounds (cisplatin + carboplatin); decreasing trends in procarbazine, nitrosoureas, mitozantrone and vinblastine consumption. Among BRM's, since 1992-1993, a decrease in consumption was observed both for immunomodulators and interferons; G-CSF consumption has increased during the last 3 years. Starting in 1992, among antiemetic drugs there was a decrease in alizapride and methoclopramide consumption contemporarily with the launch on the market of 5-HT3 antagonists; for the latter drugs, a plateau seemed to have been reached in 1995. In 1992 the highest value of costs was reached (almost 2 billion Italian lire). Since 1993 the reduction in interferons and immunomodulator agents has paralleled the reduction in total costs, reaching about 1.5 billion in 1994. In 1995 the increasing consumption of G-CSF and taxol induced an increase in total costs. Reported data could reliably reflect the reality of Italian cancer referral centres; further reports from other European institutions could be beneficial to a more extensive debate.

Original languageEnglish
Pages (from-to)641-644
Number of pages4
JournalInternational Journal of Oncology
Volume10
Issue number3
Publication statusPublished - Mar 1997

Fingerprint

Drug Costs
Referral and Consultation
Costs and Cost Analysis
Immunologic Factors
Granulocyte Colony-Stimulating Factor
Interferons
Neoplasms
Vindesine
Platinum Compounds
Procarbazine
Serotonin 5-HT3 Receptor Antagonists
Mitoxantrone
Epirubicin
Dacarbazine
Ifosfamide
Antiemetics
National Cancer Institute (U.S.)
Vinblastine
Carboplatin
Bleomycin

Keywords

  • antineoplastic drug consumption
  • cost-analysis
  • time trend analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Marfella, A., Perrone, F., Creazzola, S., Salzano, M. R., & Monfardini, S. (1997). Time trends of consumption and costs of drugs in a cancer referral centre. International Journal of Oncology, 10(3), 641-644.

Time trends of consumption and costs of drugs in a cancer referral centre. / Marfella, Antonio; Perrone, Francesco; Creazzola, Simona; Salzano, M. Rosaria; Monfardini, Silvio.

In: International Journal of Oncology, Vol. 10, No. 3, 03.1997, p. 641-644.

Research output: Contribution to journalArticle

Marfella, A, Perrone, F, Creazzola, S, Salzano, MR & Monfardini, S 1997, 'Time trends of consumption and costs of drugs in a cancer referral centre', International Journal of Oncology, vol. 10, no. 3, pp. 641-644.
Marfella A, Perrone F, Creazzola S, Salzano MR, Monfardini S. Time trends of consumption and costs of drugs in a cancer referral centre. International Journal of Oncology. 1997 Mar;10(3):641-644.
Marfella, Antonio ; Perrone, Francesco ; Creazzola, Simona ; Salzano, M. Rosaria ; Monfardini, Silvio. / Time trends of consumption and costs of drugs in a cancer referral centre. In: International Journal of Oncology. 1997 ; Vol. 10, No. 3. pp. 641-644.
@article{c069e44a78904ca59322732326fff63c,
title = "Time trends of consumption and costs of drugs in a cancer referral centre",
abstract = "This study is a descriptive analysis of the consumption and the costs of antineoplastic chemotherapeutic agents and of the major groups of drugs used for supportive therapy during the 1990-1995 period, at the National Cancer Institute of Naples, Italy. Increasing consumption trends were observed for methotrexate, vinorelbine, oxazophorines (cyclophosphamide + ifosfamide), epirubicin, dacarbazine and 5-fluorouracil; stable trends for etoposide, mitomycin C, bleomycin, vincristine + vindesine, and platinum compounds (cisplatin + carboplatin); decreasing trends in procarbazine, nitrosoureas, mitozantrone and vinblastine consumption. Among BRM's, since 1992-1993, a decrease in consumption was observed both for immunomodulators and interferons; G-CSF consumption has increased during the last 3 years. Starting in 1992, among antiemetic drugs there was a decrease in alizapride and methoclopramide consumption contemporarily with the launch on the market of 5-HT3 antagonists; for the latter drugs, a plateau seemed to have been reached in 1995. In 1992 the highest value of costs was reached (almost 2 billion Italian lire). Since 1993 the reduction in interferons and immunomodulator agents has paralleled the reduction in total costs, reaching about 1.5 billion in 1994. In 1995 the increasing consumption of G-CSF and taxol induced an increase in total costs. Reported data could reliably reflect the reality of Italian cancer referral centres; further reports from other European institutions could be beneficial to a more extensive debate.",
keywords = "antineoplastic drug consumption, cost-analysis, time trend analysis",
author = "Antonio Marfella and Francesco Perrone and Simona Creazzola and Salzano, {M. Rosaria} and Silvio Monfardini",
year = "1997",
month = "3",
language = "English",
volume = "10",
pages = "641--644",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Time trends of consumption and costs of drugs in a cancer referral centre

AU - Marfella, Antonio

AU - Perrone, Francesco

AU - Creazzola, Simona

AU - Salzano, M. Rosaria

AU - Monfardini, Silvio

PY - 1997/3

Y1 - 1997/3

N2 - This study is a descriptive analysis of the consumption and the costs of antineoplastic chemotherapeutic agents and of the major groups of drugs used for supportive therapy during the 1990-1995 period, at the National Cancer Institute of Naples, Italy. Increasing consumption trends were observed for methotrexate, vinorelbine, oxazophorines (cyclophosphamide + ifosfamide), epirubicin, dacarbazine and 5-fluorouracil; stable trends for etoposide, mitomycin C, bleomycin, vincristine + vindesine, and platinum compounds (cisplatin + carboplatin); decreasing trends in procarbazine, nitrosoureas, mitozantrone and vinblastine consumption. Among BRM's, since 1992-1993, a decrease in consumption was observed both for immunomodulators and interferons; G-CSF consumption has increased during the last 3 years. Starting in 1992, among antiemetic drugs there was a decrease in alizapride and methoclopramide consumption contemporarily with the launch on the market of 5-HT3 antagonists; for the latter drugs, a plateau seemed to have been reached in 1995. In 1992 the highest value of costs was reached (almost 2 billion Italian lire). Since 1993 the reduction in interferons and immunomodulator agents has paralleled the reduction in total costs, reaching about 1.5 billion in 1994. In 1995 the increasing consumption of G-CSF and taxol induced an increase in total costs. Reported data could reliably reflect the reality of Italian cancer referral centres; further reports from other European institutions could be beneficial to a more extensive debate.

AB - This study is a descriptive analysis of the consumption and the costs of antineoplastic chemotherapeutic agents and of the major groups of drugs used for supportive therapy during the 1990-1995 period, at the National Cancer Institute of Naples, Italy. Increasing consumption trends were observed for methotrexate, vinorelbine, oxazophorines (cyclophosphamide + ifosfamide), epirubicin, dacarbazine and 5-fluorouracil; stable trends for etoposide, mitomycin C, bleomycin, vincristine + vindesine, and platinum compounds (cisplatin + carboplatin); decreasing trends in procarbazine, nitrosoureas, mitozantrone and vinblastine consumption. Among BRM's, since 1992-1993, a decrease in consumption was observed both for immunomodulators and interferons; G-CSF consumption has increased during the last 3 years. Starting in 1992, among antiemetic drugs there was a decrease in alizapride and methoclopramide consumption contemporarily with the launch on the market of 5-HT3 antagonists; for the latter drugs, a plateau seemed to have been reached in 1995. In 1992 the highest value of costs was reached (almost 2 billion Italian lire). Since 1993 the reduction in interferons and immunomodulator agents has paralleled the reduction in total costs, reaching about 1.5 billion in 1994. In 1995 the increasing consumption of G-CSF and taxol induced an increase in total costs. Reported data could reliably reflect the reality of Italian cancer referral centres; further reports from other European institutions could be beneficial to a more extensive debate.

KW - antineoplastic drug consumption

KW - cost-analysis

KW - time trend analysis

UR - http://www.scopus.com/inward/record.url?scp=0030901487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030901487&partnerID=8YFLogxK

M3 - Article

C2 - 21533426

AN - SCOPUS:0030901487

VL - 10

SP - 641

EP - 644

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -